{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:50:34Z","timestamp":1790880634786,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ijrobp.2021.03.035","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T12:29:19Z","timestamp":1616588959000},"page":"36-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2312-5418","authenticated-orcid":false,"given":"Bradford S.","family":"Hoppe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Milgrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Bakst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie K.","family":"Ballas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouthaina S.","family":"Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul S.","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Mansur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika L.","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea C.","family":"Pinnix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Plastaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Terezakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Kirwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis S.","family":"Constine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2021.03.035_bib0001","doi-asserted-by":"crossref","first-page":"e4054","DOI":"10.1097\/MD.0000000000004054","article-title":"Racial patterns of patients with primary mediastinal large B-cell lymphoma: SEER analysis","volume":"95","author":"Liu","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0002","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0003","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ijrobp.2016.02.057","article-title":"Prognostic role of pre-radiation therapy (18)F-fluorodeoxyglucose positron emission tomography for primary mediastinal B-cell lymphomas treated with R-CHOP or R-CHOP-like chemotherapy plus radiation","volume":"95","author":"Filippi","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0004","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14951","article-title":"Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R","volume":"179","author":"Giulino-Roth","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0005","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00280-016-3024-8","article-title":"Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy","volume":"77","author":"Goldschmidt","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0006","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2013.51.7524","article-title":"[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study","volume":"32","author":"Martelli","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0007","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/bloodadvances.2018017681","article-title":"Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL","volume":"2","author":"Pinnix","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0008","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ptj\/89.9.873","article-title":"Reprint\u2014preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"89","author":"Moher","year":"2009","journal-title":"Phys Ther"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0009","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/bmj.311.7001.376","article-title":"Consensus methods for medical and health services research","volume":"311","author":"Jones","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0010","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1287\/mnsc.9.3.458","article-title":"An experimental application of the DELPHI method to the use of experts","volume":"9","author":"Dalkey","year":"1963","journal-title":"Manage Sci"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0011","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/annonc\/mdq418","article-title":"Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: Results of the Mabthera International Trial Group study","volume":"22","author":"Rieger","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0012","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/bjh.14287","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial","volume":"175","author":"Gleeson","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0013","doi-asserted-by":"crossref","first-page":"650","DOI":"10.6004\/jnccn.2019.0029","article-title":"NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019","volume":"17","author":"Zelenetz","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0014","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1200\/JCO.1993.11.8.1573","article-title":"EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma","volume":"11","author":"Wilson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0015","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3324\/haematol.2018.192492","article-title":"End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: A paradigm shift in clinical decision making","volume":"103","author":"Melani","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0016","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/leu.2015.120","article-title":"PET\/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy","volume":"30","author":"Vassilakopoulos","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0017","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijrobp.2015.02.006","article-title":"Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography","volume":"92","author":"Pinnix","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0018","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1200\/EDBK_159037","article-title":"Functional imaging using 18-fluorodeoxyglucose PET in the management of primary mediastinal large B-cell lymphoma: The contributions of the International Extranodal Lymphoma Study Group","volume":"35","author":"Cavalli","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0019","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/10428190802108870","article-title":"Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma","volume":"49","author":"Kuruvilla","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/10428194.2014.910656","article-title":"The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: Single institution experience and literature review","volume":"56","author":"Cheah","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0021","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.bbmt.2018.06.009","article-title":"Outcomes of relapsed and refractory primary mediastinal (thymic) large B cell lymphoma treated with second-line therapy and intent to transplant","volume":"24","author":"Vardhana","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0022","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41409-017-0063-7","article-title":"Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation","volume":"53","author":"Avivi","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0023","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1182\/blood-2017-01-764258","article-title":"Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: Results from a phase 2 clinical trial","volume":"129","author":"Zinzani","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0024","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0025","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: Efficacy and safety from the phase II CheckMate 436 Study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0026","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood-2010-04-278796","article-title":"Morbidity and mortality in long-term survivors of Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study","volume":"117","author":"Castellino","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0027","doi-asserted-by":"crossref","unstructured":"Oeffinger KC, Stratton KL, Hudson MM, et\u00a0al. Impact of risk-adapted therapy for pediatric Hodgkin lymphoma on risk of long-term morbidity: A report from the Childhood Cancer Survivor Study [e-pub ahead of print]. J Clin Oncol. 2021 Feb 25:JCO2001186. doi:10.1200\/JCO.20.01186.","DOI":"10.1200\/JCO.20.01186"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0028","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","article-title":"Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma","volume":"25","author":"Hodgson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0029","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ijrobp.2015.11.046","article-title":"Radiation-related new primary solid cancers in the Childhood Cancer Survivor Study: Comparative radiation dose response and modification of treatment effects","volume":"94","author":"Inskip","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0030","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1200\/JCO.18.01764","article-title":"Therapy-related cardiac risk in childhood cancer survivors: An analysis of the Childhood Cancer Survivor Study","volume":"37","author":"Bates","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0031","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: Effects of cardiac exposure to radiation and anthracyclines","volume":"129","author":"van Nimwegen","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0032","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.ijrobp.2011.05.015","article-title":"Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma","volume":"82","author":"Paumier","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0033","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.prro.2015.04.003","article-title":"Interobserver variability in clinical target volume delineation for primary mediastinal B-cell lymphoma","volume":"5","author":"Piva","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0034","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijrobp.2015.02.008","article-title":"Expert radiation oncologist interpretations of involved-site radiation therapy guidelines in the management of Hodgkin lymphoma","volume":"92","author":"Hoppe","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0035","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0036","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijrobp.2020.03.019","article-title":"Involved site radiation therapy in adult lymphomas: An overview of International Lymphoma Radiation Oncology Group Guidelines","volume":"107","author":"Wirth","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0037","series-title":"Non-Hodgkin Lymphoma Guidelines. Plymouth City, PA: National Comprehensive Cancer Network","year":"2018"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0038","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijrobp.2015.02.030","article-title":"Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: A comparison of second cancers and heart disease risk","volume":"92","author":"Filippi","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0039","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1748-717X-9-94","article-title":"Dosimetric advantages of a \u201cbutterfly\u201d technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma","volume":"9","author":"Voong","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0040","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ijrobp.2017.05.004","article-title":"Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee","volume":"99","author":"Tseng","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0041","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.prro.2019.09.015","article-title":"The meaningless meaning of mean heart dose in mediastinal lymphoma in the modern radiation therapy era","volume":"10","author":"Hoppe","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0042","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.3109\/10428194.2015.1014364","article-title":"Proton therapy in the management of non-Hodgkin lymphoma","volume":"56","author":"Sachsman","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijrobp.2021.03.035_bib0043","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: The International Lymphoma Radiation Oncology Group guidelines","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621002959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621002959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:52:14Z","timestamp":1759744334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301621002959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0360301621002959"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.03.035","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.03.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}